2 min read

Poly Medicure Moat Analysis: Score & Risks

Moat Note · First-pass

Poly Medicure Ltd.

A first-pass moat teardown of Poly Medicure Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.19 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Poly Medicure Ltd. scores 5.19 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D1Network Effects6
M · Mechanism Verified verbatim

“Focus on domestic market and increase reach to 5000 Hospitals in next 2 years”

Poly Medicure Ltd. · Annual Report · p.11
D4Price Discretion6
M · Mechanism Verified verbatim

“we are exploring some opportunities in contract manufacturing space, specifically where we see reasonable margins and we have signed two contracts in the first quarter”

Poly Medicure Ltd. · Earnings Call · p.4
D5Intangible Assets5.5
M · Mechanism Verified verbatim

“number of patent additions has been around close to nine additions, so total patents are now 334”

Poly Medicure Ltd. · Earnings Call · p.4
D3Cost Advantage5.2
M · Mechanism Verified verbatim

“I think it's very clear that there is an operating leverage play that will happen in this company as the sales increase.”

Poly Medicure Ltd. · Earnings Call · p.9
D6Efficient Scale5.2
M · Mechanism Verified verbatim

“The space is fairly consolidated with the top five players having almost 60% of market share.”

Poly Medicure Ltd. · Earnings Call · p.3
D2Switching Costs4.7
M · Mechanism Verified verbatim

“they place machines in the hospital and then because they have a larger balance sheet, they can do that. And then they work on a 5-year, 7-year contract for supplying consumables.”

Poly Medicure Ltd. · Earnings Call · p.11
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?6.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.